Syndax (SNDX) Pharmaceuticals announced new data from the pivotal AUGMENT-101 trial of Revuforj, the Company’s first-in-class menin inhibitor, in patients with relapsed or refractory mutant NPM1 and NUP98-rearranged acute myeloid leukemia. The data are being presented in posters at the 30th European Hematology Association Annual Congress Meeting being held June 12-15, 2025, in Milan, Italy and virtually. The complete remission plus complete remission with partial hematologic recovery rate was 26%. The median duration of CR/CRh response was 4.7 months and the median time to first CR/CRh was 2.8 months. The overall response rate was 48%. Of the patients who achieved an overall response, five patients proceeded to hematopoietic stem cell transplant while in remission, with three patients resuming revumenib after HSCT. Newly shared data from this single-arm trial show that the median overall survival observed was 4.8 months among all efficacy-evaluable Phase 2 R/R mNPM1 AML patients, based on the Kaplan-Meier estimate.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Syndax Pharmaceuticals: Promising 2025 Outlook and Strategic Product Launches Drive Buy Rating
- Closing Bell Movers: Trip.com slips 3% after results despite topping estimates
- Syndax exec buys $105.8K, director buys $91.1K in common stock
- Syndax Pharmaceuticals Appoints New Head of R&D
- Syndax appoints Nicholas Botwood as Chief Medical Officer